Medindia

X

Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care

Friday, September 18, 2009 General News J E 4
Advertisement


LACHEN, Switzerland and HOBOKEN, N.J., July 23 Octapharma USA is now accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in October.

Octapharma AG, the third largest plasma products manufacturer in the world, launched the grants program in celebration of its 25(th) anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"We have been committed to patient care and medical innovation since day one and our vision of providing patients with the safest, highest quality human protein therapies available is stronger than ever," said Octapharma USA President Flemming Nielsen. "The Octapharma 25(th) Anniversary Grants Program is our latest initiative to help improve the lives of people around the world."

Grant applications are accepted online only at www.octapharmagrants.com. All grant requests will be evaluated by the Octapharma 25(th) Anniversary Grants Committee in October and the first grants recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

Octapharma AG

Octapharma AG is the third largest plasma products manufacturer in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam(R) (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Based in Lachen, Switzerland, Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration, providing the highest level of production flexibility and minimizing product shortages. For more information, please visit www.octapharma.com or call Octapharma USA at 201-604-1130.

SOURCE Octapharma USA
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Bioheart Announces Acceptance of Marvel-1 Data for...
S
Connectyx Technologies Holdings Group, Inc. to Beg...